Clinical Failure Rates Rise Over Decades

**Clinical Trial Failure Rates Have Climbed Over Recent Decades, Science.org Reports**

A recent blog post on Science.org titled “Clinical failure rates over decades yikes” charts a troubling trend in pharmaceutical development: the proportion of drug candidates that fail in clinical trials has risen steadily over the past half‑century. The analysis draws on data from the FDA’s clinical trial database and peer‑reviewed studies, showing that failure rates have climbed from roughly 30 % in the early 1990s to more than 50 % in the 2010s. The authors attribute the uptick to a combination of factors, including increasingly stringent regulatory requirements, the growing complexity of disease targets, and the higher expectations for efficacy and safety that modern trials demand.

The post also highlights the implications for the industry and patients alike. With each failed candidate representing a significant financial loss—often exceeding a billion dollars in development costs—companies are under pressure to improve preclinical models and early‑stage screening methods. The authors argue that better translational tools could reduce the number of late‑stage failures, accelerating the delivery of new therapies to the clinic. They conclude by calling for a renewed focus on robust biomarker development and adaptive trial designs as a means to mitigate the rising attrition rates.